{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:19:59Z","timestamp":1778156399889,"version":"3.51.4"},"reference-count":55,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005366","name":"Universitetet i Oslo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Methadone (R,S\u2010methadone) can prolong the QT interval. R\u2010methadone inhibits cardiac potassium channel function less than S\u2010methadone. We tested if switching from methadone to R\u2010methadone would reduce corrected QT (QTc) intervals in methadone maintenance treatment (MMT) patients. Nine patients, with automatically read QTc intervals \u2265450\u2009ms, were required to detect a 20\u2009ms (clinically relevant) reduction in QTc intervals with 15\u2009ms standard deviation (SD) and 90% power. Nine stabilized MMT patients, using median (range) 70 (40\u2013120) mg methadone, were included. Data (ECG recordings, serum samples, and withdrawal symptoms) were collected both before drug intake (C<jats:sub>min<\/jats:sub>) and at 3 h after drug intake (C<jats:sub>max<\/jats:sub>), and were collected on the day before the switch from methadone to equipotent R\u2010methadone dose and at 14 and 28 days after the switch. A cardiologist calculated QTc intervals retrospectively. Serum electrolytes and methadone concentrations were measured. Mean QTc intervals at C<jats:sub>min<\/jats:sub> were 472\u2009ms and 422\u2009ms on methadone (automatically and manually read) and 414\u2009ms on R\u2010methadone (manually read). Mean (SD) change in QTc intervals was \u22128 (10) ms (<jats:italic>p<\/jats:italic>\u2009=\u20090.047) at C<jats:sub>min<\/jats:sub> but non\u2010significant at C<jats:sub>max<\/jats:sub>. R\u2010methadone showed a concentration\u2010dependent relationship with QTc intervals. Switching to R\u2010methadone reduced QTc intervals, but far less than the 20\u2009ms considered clinically relevant.<\/jats:p>","DOI":"10.1111\/bcpt.13982","type":"journal-article","created":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T09:34:01Z","timestamp":1706952841000},"page":"519-530","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect on QTc interval by switching from methadone to equipotent R\u2010methadone dose in methadone maintenance treatment patients"],"prefix":"10.1111","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6229-2246","authenticated-orcid":false,"given":"Stine Marie","family":"Havig","sequence":"first","affiliation":[{"name":"Department of Pharmacology Oslo University Hospital  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riikka Mari","family":"Berg\u2010Pedersen","sequence":"additional","affiliation":[{"name":"Department of Substance Use Disorder Treatment Oslo University Hospital  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hege\u2010Merete","family":"Krabseth","sequence":"additional","affiliation":[{"name":"Department of Pharmacology Oslo University Hospital  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lill Dannevig","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Pharmacology Oslo University Hospital  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Haugaa","sequence":"additional","affiliation":[{"name":"Department of Cardiology Oslo University Hospital  Oslo Norway"},{"name":"Institute of Clinical Medicine University of Oslo  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasse Khiabani","family":"Zare","sequence":"additional","affiliation":[{"name":"Department of Pharmacology Oslo University Hospital  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Knut","family":"Gjesdal","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine University of Oslo  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Krajci","sequence":"additional","affiliation":[{"name":"Department of Substance Use Disorder Treatment Oslo University Hospital  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mimi Stokke","family":"Opdal","sequence":"additional","affiliation":[{"name":"Department of Pharmacology Oslo University Hospital  Oslo Norway"},{"name":"Institute of Clinical Medicine University of Oslo  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,2,3]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263\u2010020\u201000743\u20103"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/978\u20101\u20104614\u20106974\u20102_2"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.038240"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12012\u2010010\u20109074\u2010y"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2023.03.006"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.272.5262.681"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100120"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000167043"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2017.03.014"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi312"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000492616"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.12.1280"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360\u20100443.2009.02549.x"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.01.013"},{"key":"e_1_2_10_16_1","unstructured":"Legemiddelassistert rehabilitering (LAR) ved opioidavhengighet. Helsedirektoratet; May 23 2022. Updated November 30 2022. Accessed August 15 2023.https:\/\/www.helsedirektoratet.no\/retningslinjer\/behandling-ved-opioidavhengighet"},{"key":"e_1_2_10_17_1","unstructured":"StrainE.Opioid use disorder: pharmacologic management. UpToDate Updated November 14 2023. Accessed December 10 2023.https:\/\/www.uptodate.com\/contents\/opioid-use-disorder-pharmacologic-management"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.273"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcdr.2013.10.001"},{"key":"e_1_2_10_20_1","unstructured":"Levometadon \u2010 fare for overdosering. Statens Legemiddelverk; December 6 2018. Updated December 7 2018. Accessed August 15 2023.https:\/\/legemiddelverket.no\/nyheter\/levometadon-fare-for-overdosering"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.26"},{"key":"e_1_2_10_22_1","unstructured":"ICH Topic E 14: the clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non\u2010antiarrhythmic drugs (CHMP\/ICH\/2\/04). European Medicine Agency; November 2005. Accessed August 15 2023.https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-14-clinical-evaluation-qt\/qts-interval-prolongation-proarrhythmic-potential-non-antiarrhythmic-drugs-step-5_en.pdf"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13114"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12862"},{"key":"e_1_2_10_25_1","unstructured":"ICH guideline E14: The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs (R3)\u2014questions and answers Step 5. European Medicine Agency; January 25 2016. Accessed August 15 2023.https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/ich\u2010guideline\u2010e14\u2010clinical\u2010evaluation\u2010qt\/qtc\u2010interval\u2010prolongation\u2010proarrhythmic\u2010potential\u2010non\u2010antiarrhythmic\u2010drugs\u2010r3\u2010questions\u2010answers\u2010step_en.pdf"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.04.009"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540\u20108159.2004.00701.x"},{"key":"e_1_2_10_28_1","unstructured":"Sample size calculation results. Statulator. Accessed January 3 2019.http:\/\/statulator.com\/SampleSize\/ss1P.html"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2003.10400007"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.120295"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13944"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1542\u2010474x.2003.08413.x"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003264"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/ftd.0000000000000437"},{"key":"e_1_2_10_35_1","unstructured":"Metadon dne (summary of product characteristcs). Den norske Eterfabrikk; April 5 2005. Updated May 11 2023. Accessed August 15 2023.https:\/\/www.legemiddelsok.no\/_layouts\/15\/Preparatomtaler\/Spc\/04-2423.pdf"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13011\u2010021\u201000367\u2010w"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2015.03.081"},{"key":"e_1_2_10_38_1","unstructured":"Methadone: pharmacokinetics (in\u2010depth answers). Merative Micromedex. Updated December 5 2023. Accessed December 10 2023.https:\/\/www.micromedexsolutions.com\/"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.04.007"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.109.192704"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13326"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010016\u20100415\u20102"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.16m11318"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010017\u20102381\u20105"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/pace.13040"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.11.035"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euv105"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/jce.13235"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213\u2010019\u201005277\u20101"},{"key":"e_1_2_10_50_1","unstructured":"WoosleyRL HeiseCW GalloT WoosleyD LambsonJ RomeroKA.QTdrugs List. AZCERT Accessed August 15 2023.https:\/\/www.crediblemeds.org"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1112"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2019.28.2"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.118.033943"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.191098"},{"issue":"8","key":"e_1_2_10_55_1","first-page":"462","article-title":"Keeping patients safe from methadone overdoses","volume":"36","author":"Grissinger M","year":"2011","journal-title":"P t"},{"key":"e_1_2_10_56_1","unstructured":"Narkotika\u2010 og dopingstatistikk 2022. Kripos; January 24 2023. Accessed December 10 2023.https:\/\/www.politiet.no\/globalassets\/tall-og-fakta\/narkotika\/narkotikastatistikk-2022.pdf"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13982","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T07:11:54Z","timestamp":1712041914000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.13982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,3]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1111\/bcpt.13982"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.13982","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,3]]},"assertion":[{"value":"2023-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}